
Ataraxis AI
AI-driven diagnostic tests enhancing precision medicine with rapid, personalized cancer prognostics.
Date | Investors | Amount | Round |
---|---|---|---|
investor investor | €0.0 | round | |
* | $20.4m | Series A | |
Total Funding | 000k |
Related Content
Ataraxis AI is a precision medicine company focused on revolutionizing cancer diagnostics through advanced AI technology. With a recent emergence from stealth mode and backed by $4 million in seed funding, Ataraxis AI has introduced its first product, Ataraxis Breast, an AI-native prognostic test for breast cancer. This test is designed to significantly improve the prediction of patient outcomes, allowing for more precise and personalized treatment plans. Operating in the healthcare sector, particularly in oncology, Ataraxis AI serves physicians and healthcare providers by offering rapid diagnostic results within one business day. The company's business model revolves around providing these AI-powered diagnostic tests, which are accessible through a physician portal or delivered directly to clinicians. By leveraging AI, Ataraxis AI aims to set a new standard in molecular diagnostics, traditionally the benchmark for personalized treatment selection. Keywords: AI, precision medicine, cancer diagnostics, breast cancer, prognostic test, oncology, personalized treatment, healthcare, molecular diagnostics, rapid results.